In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IBiomarker/Laboratory analysis, TreatmentActive1 month to 17 yearsPharmaceutical / Industry116013
NCT01677741

Trial Description

Summary

This is a 2-part, study to determine the safety, tolerability and pharmacokinetics of oral dabrafenib in children and adolescent subjects with advanced BRAF V600 mutation-positive solid tumors. Part 1 (dose escalation study) will identify the recommended Part 2 (tumor-specific expansion study) dose and regimen using a dose-escalation procedure. Approximately 6 to 18 subjects will participate in Part 1 and will receive a starting dose of 3 mg/kg and dose will deescalate or escalate between 1.5 milligram (mg)/kilogram (kg) and 6 mg/kg. Up to 6 subjects will be enrolled at one dose level dependent upon the number of subjects at the current dose level, the number of subjects who have experienced a dose limiting toxicity (DLT) at the current dose level, and the number of subjects enrolled but with data pending at the current dose level. Escalation may proceed until either a maximum tolerated dose (MTD) is established, or until the dose in which the median pharmacokinetic parameters consistent with exposure in adults are achieved. Cohorts may be added in order to evaluate additional dose levels. Part 2 consists of four disease-specific cohorts of subjects with tumors known to have BRAF V600 activation (pediatric low-grade gliomas, pediatric high-grade gliomas, Langerhans cell histiocytosis [LCH], and other tumors such as melanoma and papillary thyroid carcinoma [PTC]). Each cohort will enroll at least 10 subjects with a pre-dose and at least 1 post-dose disease assessment. In both the parts of the study, on Day 1, a single first dose will be administered, and repeat dosing will begin on Day 2. PK sampling will be performed on Day 1 and Day 15 for subjects >=25 kg in weight. For subjects <25 kg and >=10 kg in weight, blood samples for PK analysis will be collected on Day 1 and Day 15. For subjects <10kg in weight, blood samples for PK analysis will be collected after repeated administration on Day 15 only. Safety and tolerability will be assessed throughout the study. Treatment with dabrafenib will be continued until disease progression or until no clinical benefit or development of an unacceptable toxicity, or until they withdraw consent or begin a new therapy. At the end of treatment, a final study visit will occur.

Eligibility Criteria

Inclusion Criteria:

  • Written informed consent - a signed informed consent and/or assent (as age appropriate) will be obtained according to institutional guidelines.
  • Male or female >=12 months and <18 years of age at the time of signing the informed consent form.
  • Recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease. Note: Subjects with metastatic (and surgically unresectable) melanoma can be enrolled for first-line treatment; Melanoma subjects with CNS involvement may be enrolled.
  • At least one evaluable lesion.
  • BRAF V600 mutation-positive tumor as confirmed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory or equivalent (the local BRAF testing may be subject to subsequent verification by centralized testing; centralized testing can confirm V600E and V600K mutations only).
  • Performance score of >=50% according to the Karnofsky/Lansky performance status scale (subjects with a performance status of <=50% can be enrolled if the subject's confinement to bed and inability to carry out activities is due solely to cancer-related pain, as assessed by the investigator).
  • Females of child-bearing potential (with negative serum pregnancy test within 7 days prior to the first dose of study medication) must be willing to practice acceptable methods of birth control .
  • Must have adequate organ function as defined by the following values: Adequate bone marrow function defined as-absolute neutrophil count (ANC) >=1000/ microliter (µL), hemoglobin >=8.0 grams (g)/ deciliter (dL) (may receive red blood cell transfusions), platelets >=75,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment).
  • Adequate renal and metabolic function defined as: calculated glomerular filtration rate (eGFR) (Schwartz formula), or radioisotope GFR >=90 milliliters/minutes (mL/min)/1.73 meter square (m^2); or a serum creatinine within the institutional reference range upper limit of normal (for age/gender, if available).
  • Adequate liver function defined as: bilirubin (sum of conjugated + unconjugated) <=1.5 x upper limit of normal (ULN) for age, aspartate aminotransaminase (AST) and alanine transaminase (ALT) <=2.5 x ULN; AST/ALT may be <5 x ULN at baseline if disease under treatment involves the liver (requires radiographic confirmation of liver involvement).
  • Adequate cardiac function defined as: left ventricular ejection fraction (LVEF) of either >=50% by ECHO or greater than institutional lower limit of normal (LLN) by echocardiogram (ECHO) (while not receiving medications for cardiac function), corrected QT using Bazett's (QTcB) interval <450 milliseconds (msecs).

Exclusion Criteria:

  • Part 2 ONLY: Previous treatment with dabrafenib, another RAF inhibitor, or a mitogen-activated protein kinase (MEK) inhibitor (exception: prior treatment with sorafenib is permitted).
  • Malignancy OTHER than the BRAF mutant malignancy under study.
  • Had chemotherapy or radiotherapy within 3 weeks (or 6 weeks for nitrosoureas or mitomycin C) prior to administration of the first dose of study treatment.
  • The subject has received an investigational product within the following time period prior to the first dosing day in the current study: 28 days or 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is warranted by the data).
  • History of another malignancy. Exception: (a) Subjects who have been successfully treated and are disease-free for 3 years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) CLL in stable remission are eligible.
  • Current use of a prohibited medication or herbal preparation or requires any of these medications during the study.
  • Unresolved toxicity greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 Grade 2 or higher from previous anti-cancer therapy, including major surgery except those that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profile of dabrafenib (e.g., alopecia and/or peripheral neuropathy related to platinum or vinca alkaloid based chemotherapy).
  • Has leukaemia.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib and its excipients.
  • Autologous or allogeneic stem cell transplant within 3 months prior to enrolment [NOTE: subjects with evidence of active graph versus host disease are excluded].
  • History of myocardial infarction, severe or unstable angina, peripheral vascular disease or familial QTc prolongation.
  • Subjects with abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (NOTE: subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study).
  • Subjects with moderate valvular thickening.
  • Known, uncontrolled cardiac arrhythmias (except sinus arrhythmia) within the past 24 weeks
  • Uncontrolled medical conditions (e.g., diabetes mellitus, hypertension, liver disease or uncontrolled infection), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol.
  • Presence of active GI disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs.
  • Hepatitis B Virus, or Hepatitis C Virus infection (subjects with laboratory evidence of Hepatitis B Virus clearance may be enrolled).
  • Pregnant females as determined by positive human chorionic gonadotropin (hCG) test at screening or prior to dosing.
  • Lactating females who are actively breast feeding.

Trial Contact Information

Trial Lead Organizations/Sponsors

GlaxoSmithkline

GSK Clinical TrialsStudy Director

US GSK Clinical Trials Call CenterPh: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com

Trial Sites

U.S.A.
Arizona
  Phoenix
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
California
  Orange
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Maryland
  Baltimore
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Massachusetts
  Boston
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
New York
  New York
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Ohio
  Cincinnati
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Tennessee
  Memphis
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Canada
Ontario
  Toronto
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
France
  Paris cedex 05
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Villejuif Cedex
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
United Kingdom
  London
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01677741
ClinicalTrials.gov processed this data on September 22, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top